Coherent files premarket approval application (PMA) for lung cancer therapy:
This article was originally published in Clinica
Coherent has filed a supplemental PMA with the FDA for its photodynamic therapy (PDT) for the treatment of lung cancer. PDT uses laser light to stimulate a light-sensitive, cancer-specific drug to destroy host tumour cells. The light is administered to tissue that contains the drug via a fibre optic delivery system. Coherent, based in Santa Clara, California, received FDA approval last year of its PDT system for the treatment of some advanced forms of oesophageal cancer.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.